Overview

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Status:
Completed

Trial end date:
2020-10-16

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab